Ct Financial Advisors buys $2,379,518 stake in Amgen (AMGN)

Amgen (AMGN) : Ct Financial Advisors scooped up 550 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 12, 2016. The investment management firm now holds a total of 14,481 shares of Amgen which is valued at $2,379,518.Amgen makes up approximately 1.50% of Ct Financial Advisors’s portfolio.

Other Hedge Funds, Including , Canandaigua National Bank Trust Co boosted its stake in AMGN in the latest quarter, The investment management firm added 125 additional shares and now holds a total of 7,344 shares of Amgen which is valued at $1,206,766. Amgen makes up approx 0.36% of Canandaigua National Bank Trust Co’s portfolio.Catawba Capital Management Va boosted its stake in AMGN in the latest quarter, The investment management firm added 1,285 additional shares and now holds a total of 5,320 shares of Amgen which is valued at $891,100. Amgen makes up approx 0.21% of Catawba Capital Management Va’s portfolio.Central Bank Trust Co reduced its stake in AMGN by selling 283 shares or 2.34% in the most recent quarter. The Hedge Fund company now holds 11,820 shares of AMGN which is valued at $1,979,850. Amgen makes up approx 0.56% of Central Bank Trust Co’s portfolio.First American Trust Fsb reduced its stake in AMGN by selling 575 shares or 2.82% in the most recent quarter. The Hedge Fund company now holds 19,820 shares of AMGN which is valued at $3,314,697. Amgen makes up approx 1.04% of First American Trust Fsb’s portfolio.

Amgen closed down -3.99 points or -2.37% at $164.32 with 27,61,896 shares getting traded on Tuesday. Post opening the session at $167.82, the shares hit an intraday low of $163.51 and an intraday high of $167.82 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.